Alpha Cognition reported raising $1.76 Million in an initial SEC Form D filing, from an offering of $4.25 Million
PUBLIC · ACOGJan 05, 2024$1.8M of $4.2M raised
Amount Raised
$1.76 Million
$1.76 Million sold, per SEC Form D (first sale Dec 22, 2023)
Round Type
Seed
GrapevineBiotechnologyHealth CareTherapeutics
Quick answer
Alpha Cognition raised $1.76 Million in a Seed round, dated December 22, 2023. Alpha Cognition is based in Grapevine, Texas, United States.
How much did Alpha Cognition raise?
Alpha Cognition raised $1.76 Million in a Seed round on December 22, 2023.
What does Alpha Cognition do?
Alpha Cognition is a clinical stage, biopharmaceutical company dedicated to developing novel treatments for under-served neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis (ALS).
Where is Alpha Cognition based and how big is it?
Alpha Cognition is based in Grapevine, Texas, United States. Fundz records about 19 employees.
Who are the decision-makers at Alpha Cognition?
Fundz holds 2 contacts at Alpha Cognition, including the CEO and Director. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who to call at Alpha Cognition, and when
A new round usually means Alpha Cognition is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Alpha Cognition raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Alpha Cognition, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Alpha Cognition. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Alpha Cognition
Location
Grapevine, Texas, United States
About
Alpha Cognition is a clinical stage, biopharmaceutical company dedicated to developing novel treatments for under-served neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis (ALS). ALPHA-1062, a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. It is being developed as a new acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer’s type, with minimal gastrointestinal side-effects and novel routes of administration. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS. ALPHA-0602 is patented and has received Orphan Drug Designation from the FDA.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Alpha Cognition raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.